替吉奥维持治疗晚期大肠癌的临床分析(3)
 |
| 第1页 |
参见附件。
[9] 蒙燕，杨建伟.转移性结直肠癌的维持治疗[J].国际病理科学与临床杂志，2013，33(5)：412-415.
[10] 曲进，任晓安，边吉来，等.卡培他滨用于晚期胃癌术后辅助化疗患者维持治疗[J].中国医药科学，2011，1(9)：110-126.
[11] Sanoff H K，Sargent D J，Campbell M E，at al.Five-Year Data and Prognostic Factor Analysis of 0xaliplatin and Irinotecan Combinations for Advanced Colorectal Cancer：N9741[J].J Clin 0ncol，2008，26(35)：5721-5727.
[12] Koopman M，Simkens LHT，Tije AJT，at al.Maintenance treatment with capecitabine and bevacizumab versus observation after induction treatment with chemotherapy and bevacizumab in metastatic colorectal cancer(mCRC)：The phase Ⅲ CAIRO3 study of the Dutch Coloretal Cancer Group(DCCG)[J].J Clin Oncol，2013，31(suppl)：3502.
[13] Okita NT，Esaki T，Baba E，et al.A multicenter phase Ⅱ study of stop-and-go modified Folfox6 with bevacizumab for first-line treatment of patients with metastatic colorectal cancer [J].Invest New Drugs，2012，30(5)：2026-2031.
[14] Touenigand C，Liedo G，Delord J，et al. bevacizumab(BEV) with or tithout erlotinib as maince therapy，following induction first-line chemotherapy plus BEV，in patients(pts) with metastatic colorectal cancer (MCRC)：Efficacy and safety results of the International GERCOR DREAM phase Ⅲ trial [J]，J clin Oncol，2012，30(suppl)：3500.
(收稿日期：2014-07-02)
您现在查看是摘要介绍页，详见PDF附件。